Lipocine Inc.
NASDAQ:LPCN
6.08 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Lipocine Inc. |
Symbool | LPCN |
Munteenheid | USD |
Prijs | 6.08 |
Beurswaarde | 32,515,475 |
Dividendpercentage | 0% |
52-weken bereik | 2.35 - 11.79 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mahesh V. Patel Ph.D. |
Website | https://www.lipocine.com |
An error occurred while fetching data.
Over Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)